Candel Therapeutics (CADL) Interest Expenses (2022 - 2025)

Candel Therapeutics has disclosed Interest Expenses across 4 years of filings, most recently posting $1.4 million for Q4 2025.

• Interest Expenses for Q4 2025 came in at $1.4 million, up 263.08% year-over-year; the trailing twelve-month figure through Dec 2025 was $2.1 million (up 1.39% YoY), and the FY2025 annual result was $2.1 million, up 1.39% from the prior year.
• Interest Expenses came in at $1.4 million for Q4 2025 at Candel Therapeutics, up from $161000.0 in the prior quarter.
• In the past five years, Interest Expenses ranged from a high of $1.4 million in Q4 2025 to a low of $161000.0 in Q3 2025.
• The 4-year median for Interest Expenses is $567000.0 (2024), against an average of $555733.3.
• Peak annual rise in Interest Expenses reached 263.08% in 2025, while the deepest fall reached 66.94% in 2025.
• Candel Therapeutics' Interest Expenses stood at $578000.0 in 2022, then rose by 16.44% to $673000.0 in 2023, then sank by 42.05% to $390000.0 in 2024, then jumped by 263.08% to $1.4 million in 2025.
• The last three Interest Expenses figures came in at $1.4 million (Q4 2025), $161000.0 (Q3 2025), and $236000.0 (Q2 2025), per Business Quant data.